Vaxcyte (PCVX) EBITDA (2019 - 2026)

Vaxcyte (PCVX) has 8 years of EBITDA data on file, last reported at -$345.8 million in Q1 2026.

• On a quarterly basis, EBITDA fell 91.3% year-over-year to -$345.8 million in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 71.22% decrease from a year earlier, with the FY2025 full-year figure at -$923.7 million, down 62.18% from the prior year.
• EBITDA for Q1 2026 stood at -$345.8 million, down from -$274.3 million in the prior quarter.
• Over the last five years, EBITDA for PCVX reached as high as -$39.2 million in Q1 2022 and fell as low as -$345.8 million in Q1 2026.
• Historically, EBITDA has averaged -$149.4 million across 5 years, with a median of -$139.9 million in 2024.
• Across the five-year window, EBITDA slumped 190.07% in 2022 and rose 17.55% in 2024, its largest moves.
• Year by year, EBITDA stood at -$86.6 million in 2022, then plunged by 127.18% to -$196.7 million in 2023, then advanced by 17.55% to -$162.2 million in 2024, then plunged by 69.13% to -$274.3 million in 2025, then retreated by 26.09% to -$345.8 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$345.8 million in Q1 2026, -$274.3 million in Q4 2025, and -$242.4 million in Q3 2025.